At a glance
- Originator GlaxoSmithKline
- Class Benzoic acids
- Mechanism of Action Cholecystokinin A receptor agonists; Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 05 Feb 2001 No-Development-Reported for Obesity in USA (Unknown route)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 05 Feb 1998 Preclinical development for Obesity in USA (Unknown route)